Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema
The HULK trial is an open-label, multi-center study designed to assess the safety and efficacy of the administration of Zuprata to the suprachoroidal space (“suprachoroidal Zuprata”) concomitant with intravitreal aflibercept, as well as suprachoroidal Zuprata monotherapy, in patients with DME. The trial targets enrollment of approximately 20 patients, with approximately equal numbers in each of the two arms. Anatomical and functional data and safety information will be collected at each monthly visit during the 6-month evaluation period.
“In the Phase 2 TANZANITE trial of suprachoroidal Zuprata concomitant with intravitreal aflibercept in patients with macular edema due to retinal vein occlusion, or RVO, we observed encouraging visual acuity and macular edema improvements,” said Clearside’s Chief Executive Officer and President,
About Clearside
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of, and the potential market for, Clearside’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Quarterly Report on Form 10-Q for the quarter ended
Contacts Company:Charles Deignan Chief Financial Officer 678-270-4005 charlie.deignan@clearsidebio.com Investors:Matthew Beck The Trout Group 646-378-2933 mbeck@troutgroup.com